Every advance in dementia diagnosis and treatment begins with research. Currently there are 158 drugs in 192 trials in the pipeline, however, to make these new treatments possible, there is a need for thousands of people living with dementia, ranging from early, mid and late stages of the condition, to take part in clinical trials globally.
In light of this critical pivot point in Alzheimer’s disease and dementia treatments and diagnostics, ADI’s forthcoming 2026 World Alzheimer Report is focusing on clinical trials, the driving force and sole pathway for these emerging breakthroughs to reach people living with dementia, as well as inform future breakthroughs.
Join us for our upcoming World Alzheimer Report launch webinar, where leading experts and report contributors will explore the nuances dementia clinical trials, what participation means for a person living with dementia and what these trials could mean for the future of diagnosis, treatment and care.
As research continues to evolve, involving people during the early stages of dementia is increasingly important. An early diagnosis can help people access emerging treatment options, take part in clinical research where appropriate, and receive the information and support they need sooner.
Whether you’re a healthcare professional, researcher, advocate, policymaker or someone living with dementia or a carer, we invite you to be part of this important conversation.
Register today and join us as we explore the future of dementia care.
This event will be chaired by:
🔴 Chris Lynch, Acting CEO, ADI
Panellists include:
🔴 Paul Gallagher, Lead author of the 2026 World Alzheimer Report, health journalist, UK
🔴 Julie Moore, Dementia advocate, USA
🔴 Dr Emer MacSweeney, CEO, Re:Cognition Health Ltd , Consultant neuroradiologist, UK
🔴 Prof Zul Merali, Founding Director, Brain and Mind Institute, Aga Khan University, Kenya